QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Core Insights - QIAGEN N.V. has set its 2026 priorities focused on product commercialization, regulatory milestones, and automation innovations, aiming for $2 billion in combined annual sales by 2028 [1][2] Group 1: Growth Pillars - The five growth pillars identified by QIAGEN include Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics, and QuantiFERON for latent tuberculosis testing, all of which show significant growth potential [3][4] - QIAGEN plans to launch new products and submissions in 2026 to expand its market reach and enhance its automation systems, thereby increasing recurring revenues from consumables and software [2][4] Group 2: Sample Technologies - QIAGEN's acquisition of Parse Biosciences in December 2025 enhances its Sample technologies portfolio, particularly in single-cell analysis, with expected sales contribution of approximately $40 million in 2026 [4][5] - New sample preparation systems are set to launch in 2026, targeting applications such as liquid biopsy and microbiome research, which will help expand the installed base of instruments [6] Group 3: QIAstat-Dx and QIAcuity - QIAstat-Dx has exceeded 5,200 instrument placements globally by the end of 2025, with new blood culture identification panels submitted for regulatory clearance to enhance its testing menu [7] - QIAcuity digital PCR is set to expand its portfolio with new gene expression assays in 2026, further driving adoption in pharmaceutical applications [9][11] Group 4: QIAGEN Digital Insights (QDI) - QDI plans to introduce at least 14 AI-enabled software solutions by 2028, focusing on enhancing pharmaceutical R&D and clinical decision-making [12][13] - The integration of the Franklin platform with AI capabilities aims to improve genetic analysis and reporting in hereditary and oncology applications [14][15] Group 5: QuantiFERON - QIAGEN is developing a fifth generation of its QuantiFERON test, with updates planned for 2026 to meet increasing testing demands in tuberculosis diagnostics [16][17] - The new generation of chemistry for the LIAISON QuantiFERON-TB Gold Plus II assay is expected to enhance testing capacity and speed, allowing laboratories to test up to 75% more patients per hour [17][18]